E-viri
Recenzirano
Odprti dostop
-
Merritt, Kate; McGuire, Philip K; Egerton, Alice; Aleman, André; Block, Wolfgang; Bloemen, Oswald J N; Borgan, Faith; Bustillo, Juan R; Capizzano, Aristides A; Coughlin, Jennifer Marie; De la Fuente-Sandoval, Camilo; Demjaha, Arsime; Dempster, Kara; Do, Kim Q; Du, Fei; Falkai, Peter; Galinska-Skok, Beata; Gallinat, Jurgen; Gasparovic, Charles; Ginestet, Cedric E; Goto, Naoki; Graff-Guerrero, Ariel; Ho, Beng Choon; Howes, Oliver D; Jauhar, Sameer; Jeon, Peter; Kato, Tadafumi; Kaufmann, Charles A; Kegeles, Lawrence S; Keshavan, Matcheri; Kim, Sang-Young; Kunugi, Hiroshi; Lauriello, John; Liemburg, Edith Jantine; Mcilwain, Meghan E; Modinos, Gemma; Mouchlianitis, Elias D; Nakamura, Jun; Nenadic, Igor; Öngür, Dost; Ota, Miho; Palaniyappan, Lena; Pantelis, Christos; Plitman, Eric; Posporelis, Sotirios; Purdon, Scot E; Reichenbach, Jürgen R; Renshaw, Perry F; Russell, Bruce R; Sawa, Akira; Schaefer, Martin; Shungu, Dikoma C; Smesny, Stefan; Stanley, Jeffrey A; Stone, James M; Szulc, Agata; Taylor, Reggie; Thakkar, Katy; Théberge, Jean; Tibbo, Philip G; van Amelsvoort, Therese; Walecki, Jerzy; Williamson, Peter C; Wood, Stephen James; Xin, Lijing; Yamasue, Hidenori
JAMA psychiatry (Chicago, Ill.), 06/2021, Letnik: 78, Številka: 6Journal Article
Proton magnetic resonance spectroscopy (1H-MRS) studies indicate that altered brain glutamatergic function may be associated with the pathophysiology of schizophrenia and the response to antipsychotic treatment. However, the association of altered glutamatergic function with clinical and demographic factors is unclear. To assess the associations of age, symptom severity, level of functioning, and antipsychotic treatment with brain glutamatergic metabolites. The MEDLINE database was searched to identify journal articles published between January 1, 1980, and June 3, 2020, using the following search terms: MRS or magnetic resonance spectroscopy and (1) schizophrenia or (2) psychosis or (3) UHR or (4) ARMS or (5) ultra-high risk or (6) clinical high risk or (7) genetic high risk or (8) prodrome* or (9) schizoaffective. Authors of 114 1H-MRS studies measuring glutamate (Glu) levels in patients with schizophrenia were contacted between January 2014 and June 2020 and asked to provide individual participant data. In total, 45 1H-MRS studies contributed data. Associations of Glu, Glu plus glutamine (Glx), or total creatine plus phosphocreatine levels with age, antipsychotic medication dose, symptom severity, and functioning were assessed using linear mixed models, with study as a random factor. Glu, Glx, and Cr values in the medial frontal cortex (MFC) and medial temporal lobe (MTL). In total, 42 studies were included, with data for 1251 patients with schizophrenia (mean SD age, 30.3 10.4 years) and 1197 healthy volunteers (mean SD age, 27.5 8.8 years). The MFC Glu (F1,1211.9 = 4.311, P = .04) and Glx (F1,1079.2 = 5.287, P = .02) levels were lower in patients than in healthy volunteers, and although creatine levels appeared lower in patients, the difference was not significant (F1,1395.9 = 3.622, P = .06). In both patients and volunteers, the MFC Glu level was negatively associated with age (Glu to Cr ratio, F1,1522.4 = 47.533, P < .001; cerebrospinal fluid-corrected Glu, F1,1216.7 = 5.610, P = .02), showing a 0.2-unit reduction per decade. In patients, antipsychotic dose (in chlorpromazine equivalents) was negatively associated with MFC Glu (estimate, 0.10 reduction per 100 mg; SE, 0.03) and MFC Glx (estimate, -0.11; SE, 0.04) levels. The MFC Glu to Cr ratio was positively associated with total symptom severity (estimate, 0.01 per 10 points; SE, 0.005) and positive symptom severity (estimate, 0.04; SE, 0.02) and was negatively associated with level of global functioning (estimate, 0.04; SE, 0.01). In the MTL, the Glx to Cr ratio was positively associated with total symptom severity (estimate, 0.06; SE, 0.03), negative symptoms (estimate, 0.2; SE, 0.07), and worse Clinical Global Impression score (estimate, 0.2 per point; SE, 0.06). The MFC creatine level increased with age (estimate, 0.2; SE, 0.05) but was not associated with either symptom severity or antipsychotic medication dose. Findings from this mega-analysis suggest that lower brain Glu levels in patients with schizophrenia may be associated with antipsychotic medication exposure rather than with greater age-related decline. Higher brain Glu levels may act as a biomarker of illness severity in schizophrenia.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.